Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Hamlet BioPharma

5.62 SEK

+1.44 %

Less than 1K followers

HAMLET B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.44 %
+4.27 %
-4.75 %
+14.23 %
-6.49 %
+36.41 %
+43.86 %
-11.32 %
+154.01 %

Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.

Read more
Market cap
1.04B SEK
Turnover
443.56K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22/5
2026

Interim report Q3'26

28/8
2026

Annual report '26

13/11
2026

Interim report Q1'27

All
Press releases
ShowingAll content types
Press release2/23/2026, 9:00 AM

Hamlet BioPharma AB (publ): Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

Hamlet BioPharma
Regulatory press release2/13/2026, 8:00 AM

Hamlet BioPharma AB (publ): Q2 INTERIM REPORT OCT - DEC 2025

Hamlet BioPharma
Press release2/13/2026, 7:51 AM

Investor Studios: Hamlet Biopharmas ordförande presenterar rapporten live 12.00

Hamlet BioPharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/12/2026, 4:03 PM

Hamlet BioPharma AB (publ): Nature Microbiology publishes the paper `'Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.''

Hamlet BioPharma
Press release2/11/2026, 9:30 AM

Hamlet BioPharma AB (publ): Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it's Q2 report

Hamlet BioPharma
Press release2/3/2026, 9:15 AM

Hamlet BioPharma AB (publ): Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet BioPharma
Press release1/27/2026, 11:00 AM

Hamlet BioPharma AB (publ): 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet BioPharma
Press release1/16/2026, 1:00 PM

Hamlet BioPharma AB (publ): Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

Hamlet BioPharma
Press release12/18/2025, 1:30 PM

Hamlet BioPharma AB (publ): The HAMLET project featured in Cancerfonden's Christmas Campaign

Hamlet BioPharma
Regulatory press release12/4/2025, 12:00 PM

Hamlet BioPharma AB (publ): Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Hamlet BioPharma
Press release11/19/2025, 7:20 AM

BioStock: Video från Hamlet Biopharmas presentation vid BioStock Life Science Summit 2025

Hamlet BioPharma
Press release11/19/2025, 7:20 AM

BioStock: Video from Hamlet Biopharma's presentation at BioStock Life Science Summit 202

Hamlet BioPharma
Press release11/14/2025, 12:00 PM

Hamlet BioPharma AB (publ): FDA ger Hamlet BioPharma pivotal status för avgörande Fas III-studie i blåscancer

Hamlet BioPharma
Regulatory press release11/14/2025, 8:00 AM

Hamlet BioPharma AB (publ): Q1 INTERIM REPORT JULY - SEPT 2025

Hamlet BioPharma
Press release11/14/2025, 7:52 AM

Investor Studios: Hamlet Biopharmas VD presenterar rapporten live 12.00

Hamlet BioPharma
Press release11/13/2025, 9:00 AM

Hamlet BioPharma AB (publ): Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

Hamlet BioPharma
Regulatory press release11/12/2025, 9:00 AM

Hamlet BioPharma AB (publ): Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas

Hamlet BioPharma
Regulatory press release11/10/2025, 8:00 AM

Hamlet BioPharma AB (publ): Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non-Muscle Invasive Bladder Cancer

Hamlet BioPharma
Press release11/5/2025, 1:00 PM

Hamlet BioPharma AB (publ): Klinisk studie på spädbarn bekräftar Hamlet BioPharmas strategi för icke-antibiotisk behandling av infektioner

Hamlet BioPharma
Press release11/5/2025, 1:00 PM

Hamlet BioPharma AB (publ): Clinical study in infants with febrile kidney infection supports Hamlet BioPharma's strategy for non-antibiotic treatment of bacterial infections

Hamlet BioPharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.